AngioGenex
New York, US · Nevada corporation
Find your way into AngioGenex
Sign up to see every warm intro you have to AngioGenex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AngioGenex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MM
Martin MurrayNamed on SEC filing
MA
Michael AronsteinNamed on SEC filing
MS
Michael StrageNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$260K disclosed across 1 round · 2021
▶$260KraisedDec 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$260KraisedDec 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Martin MurrayExecutive Officer, Director
- Michael AronsteinExecutive Officer, Director
- Michael StrageExecutive Officer, Director
- Offering amount
- $260K
- Amount sold
- $260K
- First sale
- Dec 2021
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has AngioGenex raised?
- AngioGenex has disclosed $260K raised across 1 round.
- Where is AngioGenex headquartered?
- AngioGenex is headquartered in New York, US.